Eiger Mountains
Keyword Search
 
2018 | 2017 | 2016
DateTitle 
01/16/18Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
- End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., Jan. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today Phase 2 LIBERTY study results in pulmonary arterial hypertension (PAH) that demonstrated no improvement overall or in key subgroups for both the primary efficacy endpoi... 
Printer Friendly Version
01/08/18Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
PALO ALTO, Calif., Jan. 8, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience which spans over two decades in large pharma and specialty pharma across oncology, inflammatory disease, pulmonary disease, dermatology and rare diseases, with multiple ... 
Printer Friendly Version
01/04/18Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
- ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif., Jan. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study.  ULTRA is a randomized, placebo-controlled study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limb(s).  There is currently no FDA approv... 
Printer Friendly Version
01/03/18Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif., Jan. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.  Dr. Apelian's clinical development and regulatory experience spans 17 years between large pharma and biotechnology companies in all phases of development ranging from discovery to registration, across m... 
Printer Friendly Version
01/02/18Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
PALO ALTO, Calif., Jan. 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will present a corporate update at Biotech Showcase™ 2018 on January 8th at 2:00 pm PT at the Hilton San Francisco (Franciscan – B Ballroom Level).  The corporate update will include a discussion of recent progress across all Eiger programs including Hepatitis ... 
Printer Friendly Version